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A B S T R A C T
Background: Whether depression risk starts increasing before cancer diagnosis, and whether cancer is an in-
dependent risk factor for depression, remain unclear. We aimed to quantify the risk of depressive symptoms
before and after the first hospitalisation for cancer (as a proxy for cancer diagnosis) amongst patients with
cancer.
Methods: We linked cohort data with national hospitalisation records in the Czech Republic. We followed 1056
incident cancer cases for up to 15 years before and 15 years after the first hospitalisation for cancer. Depressive
symptoms were measured using the Centre for Epidemiological Studies-Depression (CES-D) scale. We used
multilevel ordered logistic regression to assess the relationship between follow-up years (pre- and post-hospi-
talisation) and depressive symptoms amongst incident cancer cases. Propensity Score Matching was employed to
match each case with a cancer-free control, to test the independent effect of cancer on depressive symptoms over
time.
Results: Per one year of follow-up (whether pre- or post- hospitalisation) was associated with 1.07 (1.05–1.10)
times more likely to have high severity of depressive symptoms amongst patients with cancer. The probability of
having high severity of depressive symptoms increased from 25% at five years before hospitalisation to 33% at
7.5 years after hospitalisation. In parallel analyses amongst matched cancer-free controls, the risk of depressive
symptoms had no significant changes during follow-up.
Limitations: Stratified analyses based on cancer types and stages of malignancy were infeasible.
Conclusions: The excess risk of depressive symptoms was apparent five years prior to the first hospitalisation for
cancer. Using cancer-free matched controls, we confirmed that cancer was an independent predictor of de-
pressive symptoms.
1. Introduction
There is evidence that the prevalence of mental disorders amongst
patients with cancer is higher than that amongst the general popula-
tion, and that survival rates amongst patients with cancer and co-
morbid anxiety or depression are significantly lower than those for the
general population (Batty et al., 2017; Kisely et al., 2013; Pitman et al.,
2018; Zhu et al., 2017). Clinically, depression in patients with cancer
tends to be under-recognised, with depressive symptoms such as an-
orexia, weight loss, fatigue and insomnia often attributed to the somatic
effects of cancer rather than depression (Lloyd-Williams, 2000). The
World Health Organization (WHO) suggests that the risk of mental
disorders in patients with cancers is routinely overlooked and should be
better understood (World Health Organization, 2017).
Previous work has shown an excess risk of mental disorders
(Dalton et al., 2009; Lu et al., 2016; Mallet et al., 2018; Suppli et al.,
2014), and of suicide (Henson et al., 2018), after cancer diagnosis, with
risks more marked in cancers with poor prognosis. For example, a po-
pulation-based study in England indicated that patients with mesothe-
lioma had the highest suicide risk amongst all patients after cancer
diagnosis (Henson et al., 2018). A Danish registry-based study found a
general pattern of an increased risk of depression in the first year after
cancer diagnosis, with decreasing but still significant excess risk in
subsequent years for most types of cancer (Dalton et al., 2009). A recent
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study reported that the risk of mental disorders after cancer diagnosis in
the United States (US) was significantly higher amongst patients with a
prior history of mental disorders compared with those without psy-
chiatric histories (Mallet et al., 2018). A Swedish registry-based study
suggested that risk of mental disorders both before and after cancer
diagnosis increased to a greater extent amongst patients with cancers of
poor prognosis (i.e. lung and colorectal cancers) compared with pa-
tients with other cancers (i.e. breast cancer) (Lu et al., 2016). Generally
risk of depression and anxiety applies at all points in the cancer tra-
jectory, whether in curative or palliative treatment (Burgess et al.,
2005; Fallowfield et al., 1990; Mitchell et al., 2011).
The onset of depression in relation to cancer diagnosis requires
careful study, as it provides clues as to the aetiology of depression in the
cancer context, including the putative effect of cancer-related in-
flammation on mental disorders (Messay et al., 2012). Previous work
has shown that the excess risk of depression is apparent in the year
before cancer diagnosis, corresponding with the period of cancer di-
agnostic workup (Lu et al., 2016). This suggests that direct neu-
ropsychiatric effects may be involved even before an awareness of
cancer diagnosis, at which point predominant explanations for de-
pression or anxiety involve biopsychosocial processes (Pitman et al.,
2018). The majority of work describing the association between cancer
and depression derives from high-income countries, including the US,
England, Denmark, Australia and Sweden (Batty et al., 2017;
Burgess et al., 2005; Dalton et al., 2009; Fallowfield et al., 1990;
Henson et al., 2018; Kisely et al., 2013; Lu et al., 2016; Suppli et al.,
2014; Zhu et al., 2017). However, the generalisability of these findings
to more recent years or amongst other populations is questionable.
To address the research gap, our 16-year longitudinal study aimed
to assess the risk of depressive symptoms before and after the first
hospitalisation for cancer (as a proxy for cancer diagnosis) in the Czech
Republic. We investigated whether and when depressive symptoms
occur before the first hospitalisation for cancer. We also used matched




Data were from the Health, Alcohol and Psychosocial factors In
Eastern Europe (HAPIEE) study – Czech cohort, a prospective cohort
study of a representative sample of 8857 individuals (response rate:
82%) aged 45–69 years at baseline in the Czech Republic (Peasey et al.,
2006). Random samples stratified by gender and five-year age groups
were selected from population registers. Written informed consent was
obtained from all participants. The study received ethical approval from
the ethics committee at University College London, UK (99/0081). We
used data from baseline wave (2002–2005), wave 2 (2006–2008) and
follow-up postal surveys in 2009, 2012, 2013, 2016 and 2017. The
information on cancer diagnosis was obtained from the national hos-
pitalisation records (2001–2017) of all participants, which contain in-
formation on, for example, dates of admission and discharge, ICD codes
of primary, operation and other diagnosis, and whether being hospi-
talised for the first time for each diagnosis. We included 1056 (473
women) incident cancer cases (2003–2017) (Supplementary Figure S1),
who were matched with population-based controls (matching ratio:
1:1) using Propensity Score Matching (PSM) (Rosenbaum and




Depressive symptoms were measured using the Centre for
Epidemiological Studies-Depression (CES-D) scale (Radloff, 1977), and
used as a time-varying outcome. The format of the CES-D scale used at
baseline (CES-D-20; original 20-item measure, 4-category response)
differed at Wave 2 (2006–2008), the 2009 postal surveys (CES-D-10;
10-item measure, Boston scale; 2-category response), and the
2012–2017 postal surveys (CES-D-10; 10-item measure, Andresen scale;
4-category response) (Kohout et al., 1993; Mohebbi et al., 2018).
Cronbach's alpha values were all above 0.70, indicating acceptable
reliability (Heale and Twycross, 2015). To maintain the integrity of the
scale, up to four, one and one missing items, respectively, were allowed
for calculating the sum scores based on original, Boston and Andresen
scales. We substituted the mean values for missing items then summed
all items (Kohout et al., 1993). For comparability of results over time,
we organised sum scores into tertiles based on the entire sample size.
High severity of depressive symptoms was defined as the highest tertile
of CES-D scores.
2.2.2. Incident cancer cases
We identified incident cancer cases in cancer-free individuals at
baseline, measured as the first ever hospitalisation for any cancer (ICD-
10: C00–C97) recorded on the national hospitalisation register during
follow-up (as a proxy for cancer diagnosis), on a date later than the
dates of baseline interview. Supplementary Figure S1 and Figure S2
illustrate the numbers of incident cancer cases (2003–2017), and the
numbers of each type of cancer, respectively.
2.2.3. Follow-up years
We calculated each participant's number of years of follow-up using
the date of depressive symptom measurement in each wave of data
collection minus the date of the first hospitalisation for any cancer. The
date of the first cancer hospitalisation (a proxy for diagnostic year) was
set at zero. Negative and positive values designated pre-hospitalised
(−15.0 to −0.1) and post-hospitalised (0.1 to 15.0) years.
Supplementary Figure S3 shows a normal distribution of follow-up
years.
2.2.4. Confounders
We selected confounders based on previous evidence (Batty et al.,
2017; Bortolato et al., 2017; Burgess et al., 2005;
World Health Organization, 2017): baseline gender; age; marital status;
education; smoking; alcohol use; fruit consumption; vegetable con-
sumption; weekly hours of physical activity; diagnosed cardiovascular
disease (CVD), diabetes and chronic respiratory diseases; and Body
Mass Index.
2.3. Statistical methods
We conducted univariate analysis of baseline relationships between
confounders and depressive symptoms. We used multilevel ordered
logistic regression to assess the longitudinal relationship between
follow-up years and depressive symptoms amongst incident cancer
cases, allowing for random intercepts. Multilevel modelling can handle
attrition and wave non-response (which allows us to include incident
cancer cases who died during the post-diagnostic period), unequal time
spaces, and the inclusion of time-varying and between-individual cov-
ariates that are either continuous or discrete measures (Curran et al.,
2010).
A time-cohort model (repeat follow-up year model controlling for
baseline age group) was estimated with full adjustment. We included
year as a linear, quadratic, and a cubic term, to detect non-linear ef-
fects. We predicted the overall average probability of being in the
highest tertile of CES-D scores in each year, considering both fixed and
random effects based on this model. We fitted curves using kernel-
weighted local polynomial smoothing to explore non-linear effects of
follow-up years, allowing the data to “speak for themselves” by fitting
the response to a polynomial form of the regressor via locally weighted
least squares (Gasser and Müller, 1979). We produced curves within a
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thirty-year range (15 pre-hospitalised years and 15 post-hospitalised
years).
To test the independent effect of cancer on depressive symptoms
over time, we used PSM to match each incident cancer case with a
cancer-free participant based on similar propensity scores obtained
from a logistic regression model adjusting for all aforementioned con-
founders (Rosenbaum and Rubin, 1983). The nearest neighbour
matching was used (calliper bound=0.04, mean bias=1.8%)
(Rubin, 1973). As a result, the observed baseline characteristics became
very similar between incident cancer cases and those of cancer-free
controls (Supplementary Table S1). In order to compare risk of de-
pressive symptoms before and after a hypothetical non-cancer diagnosis
date in cancer-free controls, each control was allocated a non-exposure
data, which was the date of the first cancer hospitalisation of his or her
matched treated participant. We assessed the unadjusted relationships
between follow-up years and depressive symptoms in both groups. We
also predicted the overall probabilities of being in the highest tertile of
CES-D scores after year=0 in both groups.
We conducted a post hoc analysis to confirm whether the risk of
depressive symptoms did indeed increase in the five years prior to the
first cancer hospitalisation. For this, we applied fully-adjusted piece-
wise regression with three segments separated by two “knots” (at year
−5 and 0) (Ryan and Porth, 2007), to quantify the slope changes of the
probability of being in the highest tertile of CES-D scores. Three in-
dependent variables were included in piecewise regression, reflecting
three segments: ‘6–15 years before hospitalisation’ ‘1–4 years before
hospitalisation’ and ‘1–15 years after hospitalisation’.
2.3.1. Sensitivity analyses
We compared baseline characteristics between the analysed
(N = 1056) and excluded incident cancer cases (N = 181), to explore
whether missing data were likely to bias findings. We also employed
another harmonisation strategy – converting the CES-D sum scores into
z-scores (mean [S.D.] =0 [1]) and re-run the fully-adjusted model
using the continuous z-scores, which helps predict the overall changes
of depressive symptoms over time, and make further comparison with
other samples.
All analyses were performed using Stata SE 15 (StataCorp, 2017),
with a p-value threshold of <0.05 for statistical significance.
3. Results
3.1. Baseline sample characteristics
Table 1 presents baseline sample characteristics amongst incident
cancer cases. Over half (55%) this sample were men. Participants were
mainly aged between 50 and 69 years, married or cohabiting, and had
vocational or secondary education at baseline. Around 30% of partici-
pants were current smokers. Around 15% of participants consumed
alcohol more than 5 times per week. Participants consumed a mean of
3.48 (S.D. = 3.52) and 3.13 (S.D. = 2.25) portions of fruit and vege-
table per day, respectively. The mean hours spent on physical activity
per week were 13.49, but with wide variation (S.D. = 12.50). The
majority of the participants were diagnosed with diabetes, CVD, or
Fig. 1. Flowchart of sample selection
a20 individuals with baseline cancer-free records were re-categorised as patients with cancer at baseline since they were diagnosed with cancer before entering the
HAPIEE cohort according to their first hospitalisation records.
HAPIEE: Health, Alcohol and Psychosocial factors In Eastern Europe.
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chronic respiratory diseases, and 45% and 34% were pre-obese and
obese, respectively.
Our sample contained more than twenty types of cancer. The sample
sizes of different types of cancer were diverse (Supplementary Figure
S2). For example, there were 102, 118 and 141 incident cases of lung
(C33, C34), breast (C50) and prostate (C61) cancers, respectively;
whereas there were only 3, 23, 18 incident cases of oesophagus (C15),
stomach (C16) and brain cancers, respectively.
Supplementary Table S2 shows the univariate relationships between
confounders and depressive symptoms amongst incident cancer cases.
Participants who were female, unmarried, diagnosed with cardiovas-
cular or chronic respiratory diseases, or had vocational or primary
education or below, were more likely to have depressive symptoms at
baseline than those who were male, married, diagnosed without car-
diovascular or chronic respiratory diseases, or who had a university
degree. However, compared with non-alcohol consumers, alcohol con-
sumers were less likely to have depressive symptoms at baseline.
3.2. Association between follow-up years and depressive symptoms
Table 2 shows the results of our fully-adjusted model describing the
association between follow-up years and depressive symptoms amongst
incident cancer cases. After controlling for covariates, years of follow-
up were positively associated with severity of depressive symptoms. For
each year of observation, patients with cancer were 1.07 (95%CI:
1.05–1.10) times more likely to be in the highest tertile of CES-D scores
(whether pre- or post-diagnosis). We also found significant quadratic
and cubic effects of year, suggesting a non-linear effect of year on de-
pressive symptoms.
Fig. 2 illustrates the predicted probability of being in the highest
tertile of CES-D scores during follow-up amongst incident cancer cases,
with year=0 as a proxy for cancer diagnosis. Overall, although the
change in probability between two subsequent years was small, the
cubic shape of the curve was statistically significant (Table 2, 0.9997,
95%CI: 0.9994–0.9999). The probability was around 25% at five years
Table 1
Baseline sample characteristics amongst incident cancer cases (N = 1056).
Risk factors Total CES-D scores – lowest tertile
(39.68%)
CES-D scores – middle tertile
(33.62%)
CES-D scores – highest tertile
(26.70%)
Gender (%)
Men 55.21 43.57 33.79 22.64
Women 44.79 34.88 33.40 31.71
Age (%)
<50 years 6.16 38.46 26.15 35.38
50–59 years 32.10 38.35 32.15 29.50
60–69 years 59.09 40.06 35.26 24.68
≥70 years 2.65 50.00 32.14 17.86
Marital status (%)
Married/Cohabiting 74.91 43.24 34.01 22.76
Single/Divorced/Separated 14.20 30.67 35.33 34.00
Widowed 10.89 26.96 28.70 44.35
Education (%)
University degree 13.83 50.68 26.03 23.29
Secondary education 35.04 41.62 33.51 24.86
Vocational education 38.26 37.87 36.39 25.74
Primary education or below 12.88 27.94 33.82 38.24
Smoking (%)
Non-smokers 37.88 38.25 34.25 27.50
Previous smokers 32.10 39.82 36.87 23.30
Current smokers (<1 cigarette per day) 1.80 36.84 47.37 15.79
Current smokers (≥1 cigarette per day) 28.22 41.61 28.19 30.20
Alcohol consumption (%)
Non-alcohol consumers 12.31 29.23 36.15 34.62
<1 time per month 25.28 40.82 31.46 27.72
1–3 times per month 20.64 38.53 33.94 27.52
1–4 times per week 26.33 40.29 33.45 26.26
≥5 times per week 15.44 46.63 34.97 18.40
Physical activity (hours per week)
Mean (S.D.) 13.49 (12.50) 14.07 (12.54) 13.44 (12.69) 12.70 (12.21)
Fruit consumption (portions per day)
Mean (S.D.) 3.48 (3.52) 3.59 (3.51) 3.44 (3.98) 3.37 (2.84)
Vegetable consumption (portions per day)
Mean (S.D.) 3.13 (2.25) 3.17 (2.00) 3.08 (2.44) 3.14 (2.35)
Diabetes (%)
No 86.84 40.13 33.48 26.39
Yes 13.16 36.69 34.53 28.78
Cardiovascular disease (%)
No 83.62 40.77 33.41 25.82
Yes 16.38 34.10 34.68 31.21
Chronic respiratory diseases (%)
No 83.05 42.42 33.07 24.52
Yes 16.95 26.26 36.31 37.43
Body Mass Index (%)
Normal weight (BMI 18.5 to 24.9) 20.83 40.91 26.36 32.73
Pre-obesity (BMI 25.0 to 29.9) 44.79 39.53 36.15 24.31
Obesity (BMI ≥ 30.0) 34.38 39.12 34.71 26.17
CES-D: Centre for Epidemiological Studies-Depression; S.D.: Standard Deviation; BMI: Body Mass Index.
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before hospitalisation, and increased to around 32% at five years after
hospitalisation. Thereafter, the probability continued increasing at a
slower rate until its highest point (around 33%) at 7.5 years after
hospitalisation. The predicted values prior to 10 years pre-hospitalisa-
tion or after 10 years post-hospitalisation were dispersed, due to the
small sample size for those followed-up for more than 10 years before
or after hospitalisation (Supplementary Figure S3). The fitted curve
prior to 10 years pre- or 10 years post-diagnosis could therefore be
subject to biased interpretation.
3.3. Independent effect of cancer on depressive symptoms
Table 3 presents the results of multilevel models comparing incident
cancer cases and matched cancer-free controls. Patients with cancer
were at a significantly increased risk of high depressive symptom
burden over time, whether in linear (1.07, 95%CI: 1.05–1.10) or non-
linear models. In the cancer-free group, both linear and non-linear ef-
fects of follow-up year were non-significant. Supplementary Figure S4
compares the predicted probabilities of being in the highest tertile of
CES-D scores after hospitalisation between cancer and cancer-free
groups. For the cancer-free group, the probability did not change over
time, but for the incident cancer group, it increased for around five
years post- hospitalisation, and thereafter continued increasing but at a
slower rate, to its highest point at 7.5 years. Participants with cancer
had significantly greater probabilities of higher depressive symptoms
than cancer-free controls from around three years to twelve years post-
hospitalisation, suggesting an independent effect of cancer on depres-
sive symptoms after hospitalisation.
3.4. Slope change of the probabilities of trajectory of depressive symptoms
The results of piecewise regression (Table 4) found that the slope
change of the curve was statistically significant at five years before
hospitalisation (0.12, 95%CI: 0.07–0.18), confirming that the prob-
ability of being in the highest tertile of CES-D scores started to increase
at a greater rate at five years before hospitalisation. Although the
Table 2
Fully-adjusted multilevel models for associations between years of follow-up
(over the whole period of observation) and depressive symptom scores amongst
incident cancer cases (N = 1056).
Fixed effects ORs (95%CIs) P-values
Year 1.07 (1.05–1.10) <0.001
Year2* 1.0020 (1.0001–1.0039) 0.037
Year3* 0.9997 (0.9994–0.9999) 0.005
Gender
Men (reference)
Women 1.45 (1.12–1.89) 0.005
Age
<50 years (reference)
50–59 years 1.26 (0.78–2.05) 0.341
60–69 years 1.11 (0.69–1.78) 0.671
≥70 years 0.90 (0.40–2.04) 0.802
Marital status
Married/Cohabiting (reference)
Single/Divorced/Separated 1.51 (1.09–2.10) 0.013
Widowed 2.41 (1.66–3.49) <0.001
Education
University degree (reference)
Secondary education 0.89 (0.64–1.24) 0.493
Vocational education 1.11 (0.80–1.55) 0.539
Primary education or below 1.93 (1.23–3.04) 0.004
Smoking
Non-smokers (reference)
Previous smokers 0.83 (0.64–1.09) 0.188
Current smokers (<1 cigarette per day) 0.62 (0.27–1.40) 0.246
Current smokers (≥1 cigarette per day) 0.96 (0.72–1.28) 0.777
Alcohol consumption
Non-alcohol consumers (reference)
<1 time per month 0.95 (0.64–1.42) 0.818
1–3 times per month 0.88 (0.58–1.33) 0.543
1–4 times per week 1.05 (0.70–1.58) 0.820
≥5 times per week 0.77 (0.49–1.22) 0.271
Physical activity (hours per week) 1.00 (0.99–1.01) 0.615
Fruit consumption (portions per day) 0.97 (0.94–1.00) 0.084
Vegetable consumption (portions per day) 0.99 (0.94–1.05) 0.856
Diabetes
No (reference)
Yes 1.27 (0.91–1.77) 0.167
Cardiovascular disease
No (reference)
Yes 2.00 (1.46–2.74) <0.001
Chronic respiratory diseases
No (reference)
Yes 1.69 (1.25–2.29) 0.001
Body Mass Index
Normal weight (BMI 18.5 to 24.9) (reference)
Pre-obesity (BMI 25.0 to 29.9) 1.04 (0.78–1.40) 0.791
Obesity (BMI ≥ 30.0) 1.21 (0.88–1.67) 0.232
Thresholds Log-odds S.E.
Cut1 0.08 (−0.64–0.79) 0.36
Cut2 1.71 (0.99–1.91) 0.37
Random effects Variance (95%CI) S.E.
Individual level 1.55 (1.26–1.91) 0.16
OR: Odds Ratio; 95%CI: 95% Confidence Interval; BMI: Body Mass Index; S.E.:
Standard Error.
⁎ Year2: quadratic term of year; Year3: cubic term of year.
Fig. 2. Predicted probabilities of being in the highest tertile of CES-D scores
over time amongst incident cancer cases (N = 1065)
CES-D: Centre for Epidemiological Studies-Depression.
Table 3
Associations between follow-uptime (years) and depressive symptoms in cancer
(N = 1056) and cancer-free* (N = 1056) groups.




Fixed effects ORs (95%CIs) P-values ORs (95%CIs) P-values























Individual level 1.87 (1.53–2.27) 0.19 2.24 (1.87–2.68) 0.20
OR: Odds Ratio; 95%CI: 95% Confidence Interval; S.E.: Standard Error.
⁎ Each cancer free control was allocated a non-exposure data, which was the
date of first cancer hospitalisation of his/her matched cancer case.
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probability continued to increase after year of hospitalisation (0.07,
95%CI: 0.01–0.13), this rate of change was not statistically significant
(−0.05, 95%CI: −0.12–0.13).
3.5. Sensitivity analyses
Compared with participants included in our analysis, excluded
participants had lower education and consumed less alcohol, but were
more likely to have CVD and high CES-D scores at baseline
(Supplementary Table S3). Besides, we found similar results when using
the z-scores of CES-D to test the relationship between follow-up years
and depressive symptoms (Supplementary Table S4).
4. Discussion
4.1. Main findings
In this 16-year cohort study of 1056 incident cancer cases, we found
a positive association between years of follow-up and depressive
symptoms, covering the period both before and after the date of the first
hospitalisation for cancer that we used as a proxy for cancer diagnosis.
We found that the risk of depressive symptoms started increasing at five
years before hospitalisation, and continued to increase until 7.5 years
after hospitalisation. The most likely explanation is that our proxy for
cancer diagnosis (the first hospitalisation for cancer) was much later
than actual cancer diagnosis. However, even assuming a lag time of one
year from diagnosis to the first hospitalisation, a four-year period of
excess risk for depression prior to diagnosis is surprising, and highly
suggestive of direct neuropsychiatric explanations. Using PSM, we
confirmed that cancer was an independent predictor of depressive
symptoms.
4.2. Results in the context of other studies
Other work has found the risk of mental disorders to increase prior
to cancer diagnosis, including analysis of Swedish registers (Lu et al.,
2016), in which risk of depression, anxiety, substance abuse, somato-
form/conversion disorder, and stress reaction/adjustment disorder in-
creased from 10 months before cancer diagnosis, peaked during the first
week after diagnosis, and decreased rapidly thereafter, but remained
elevated 10 years after diagnosis. Our findings also provide one ex-
planation for the increased risk of suicide after a cancer diagnosis
(Henson et al., 2018). Our finding of an excess risk of depressive dis-
orders even prior to hospitalisation (used as a proxy for diagnosis), is
consistent with previous work (Lu et al., 2016), prompting speculation
about potential explanations. A pre-diagnostic phase of cancer-related
systemic inflammation has been proposed (Mallet et al., 2017), leading
to microglial dysfunction that is associated with psychiatric disorders
including depression (Diakos et al., 2014; Krishnan and Nestler, 2008;
Reus et al., 2015). It is possible that systemic inflammation contributes
to the risk of depressive symptoms, effecting behavioural, affective and
cognitive changes that are consistent with major depressive symptoms
(Krishnan and Nestler, 2008; Messay et al., 2012).
Explanations involving systemic inflammatory effects are somewhat
weakened by the similarities in risk of mental disorders before cancer
diagnosis when comparing patients with localised or non-metastatic
cancers and those with locally advanced or metastatic cancers (Lu et al.,
2016). An alternative physiological explanation is that non-in-
flammatory cancer symptoms before diagnosis, such as anaemia, are
associated with depression (Onder et al., 2005). A Swedish study esti-
mated the risk of cancer in relation to haemoglobin concentration (a
marker of anaemia) during the five years before cancer diagnosis,
finding a long-duration of haemoglobin decline before cancer diagnosis:
haemoglobin concentration had started declining three years before
cancer diagnosis for malignancies including stomach cancer, multiple
myeloma and lymphatic leukaemia (Edgren et al., 2010). It is also
possible that depressive symptoms are the presenting complaint for
specific cancers with neuropsychiatric effects (Benros et al., 2009), in-
cluding pancreatic cancer, pituitary tumours, and non-small cell lung
cancer (Makrilia et al., 2009; Pitman et al., 2018), although these are in
the minority.
Biopsychosocial explanations are also possible, including the effect
of rumination about pre-diagnostic cancer symptoms and the psycho-
logical stress of undergoing clinical evaluation for a suspected malig-
nancy (Lu et al., 2017). Psychological stress relating to a cancer diag-
nosis can itself can have physiological effects (such as sustained stress
causing activation of the hypothalamo-pituitary-adrenal axis), giving
rise to psychological symptoms that can reach diagnostic thresholds for
depression (Pitman et al., 2018). Psychological stress following cancer
diagnosis, including the stress of treatment, might also activate in-
flammatory pathways, with a bidirectional association with low mood
(Messay et al., 2012).
4.3. Strengths and limitations
We used a population-based representative sample to investigate an
important yet under-researched clinical question in a geographical re-
gion with a high prevalence of alcohol-related risk factors for cancer
(World Health Organization, 2018). Using routine clinical data, we
examined time trends over a period of up to 15 years prior to the first
hospitalisation for cancer, and 15 years after the first hospitalisation,
including a validated measure of depressive symptoms (Kohout et al.,
1993; Radloff, 1977). We used advanced statistical methods, including
multilevel modelling, to predict the trajectory of the probabilities of
depressive symptoms before and after the first hospitalisation for
cancer, piecewise regression to quantify the slope changes in this tra-
jectory, and propensity score matched controls to explore whether
cancer was an independent risk factor for depression.
This study has several limitations. Firstly, we excluded 181 incident
cancer cases due to missing data for depressive symptoms and con-
founders. Given the differences between included and excluded cases, it
is possible that our analysis underestimated the effects of education,
alcohol consumption and CVD on depressive symptoms.
Secondly, due to a lack of dates of cancer diagnosis in outpatient
clinics, we ascertained cancer diagnosis using the first hospitalisation
for cancer, thereby defining the date of the first cancer hospitalisation
as a proxy for cancer diagnostic date may have been later than the date
of cancer diagnosis at outpatient clinics, particularly for cancers of the
blood and skin. However, even assuming a lag time of one year from
outpatient diagnosis to the first hospitalisation, a four-year period of
Table 4
Changes of the probability of being in the highest tertile of CES-D scores at 6–15 and 1–4 years before hospitalisation s, and 1–15 years after hospitalisation.
Probabilities Slope (change per year) 95%CIs P-values
6–15 years before hospitalisation −0.06 (−0.10–−0.02) 0.007
1–4 years before hospitalisation 0.11 (0.07–0.15) <0.001
Change (between 6 and 15 years and 1–4 years before hospitalisation) 0.12 (0.07–0.18) <0.001
1–15 years after hospitalisation 0.07 (0.01–0.13) 0.024
Change (between 1 and 4 years before hospitalisation and 1–15 years after hospitalisation) −0.05 (−0.12–0.03) 0.250
CES-D: Centre for Epidemiological Studies-Depression; 95%CI: 95% Confidence Interval.
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excess risk for depression prior to cancer diagnosis from our analysis, is
highly suggestive of direct neuropsychiatric explanations.
Thirdly, stratified analysis by cancer types was not conducted due to
the small sample size for each type of cancer, although this variable was
available (Supplementary Figure S2). In the Czech Republic, first hos-
pitalisation for cancer can occur at any of I-III clinical stages of cancer
(National Cancer Control Programme, 2011). However, we lacked a
measure of cancer stage at first hospitalisation, which is likely to in-
fluence psychological health and suicide risk (Bjorkenstam et al., 2005).
Information on antidepressant prescriptions was unknown. Anti-
depressants may influence cancer risk by affecting the immune system,
representing as a potential confounder of the cancer – depression re-
lationship (Steingart and Cotterchio, 1995). We also lacked a measure
of the proportion of admissions involving emergency presentations
(Herbert et al., 2019), so could not include these in our interaction tests.
Variations in cancer types, stages of malignancy, antidepressant use and
emergency presentations could explain the individual-level residuals in
random effects in the fully-adjusted model in Table 2. Future stratified
analyses by cancer types and stages of malignancy based on cohort
studies with larger sample sizes are needed.
Fourthly, our outcome was a self-rated measure of depressive
symptoms rather than a clinical diagnosis of depression, creating the
potential for reporting bias. However, the CES-D scale is capable of
distinguishing the severity of depression and providing valid informa-
tion on which to base decisions about psychiatric treatment
(Kohout et al., 1993; Radloff, 1977). We harmonised sum CES-D scores
using tertiles, making it more difficult to compare our results with other
samples, as tertiles were dependant on the dataset used for the current
analysis (Bennette and Vickers, 2012). However, we found similar re-
sults for the main relationship when using z-scores of CES-D (Supple-
mentary Table S5), suggesting that different harmonisation strategies
would not bring bias for the true relationship. Our findings are also
consistent with previous evidence (Lu et al., 2016).
Lastly, our univariate analysis found that alcohol consumers were
less likely to have depressive symptoms than non-alcohol consumers at
baseline. Previous studies have suggested a U-shaped relationship be-
tween frequency of alcohol consumption and mortality amongst US
middle-aged and older adults (Thun et al., 1997) and British men
(Marmot et al., 1981) as well as in relation to psychological distress
amongst young British adults (Power et al., 1998). One explanation for
this pattern is that the low consumption group includes former heavy
drinkers, who stopped drinking due to worsening health or chronic
medical conditions, and who may also be at higher risk of mental health
problems (Boden and Fergusson, 2011). It is possible that in our study
non-alcohol consumers included abstainers who are more likely to have
severe depressive symptoms associated with previous misuse than the
current alcohol consumers. However, 15% of patients with cancer in
this study consumed alcohol more than 5 times per week, suggesting
that this group were likely to have an alcohol misuse disorder. Our
categorical variable describing alcohol use provided little detail on
quantities consumed, and relied on the assumption of each drinking
session being equivalent. Without greater granularity in this variable,
and also lacking a variable describing presence or absence of alcohol
misuse disorder, we cannot infer the reasons for this surprising asso-
ciation.
4.4. Clinical implications
To our knowledge, this is the first study examining risk of depressive
symptoms before and after the first hospitalisation for cancer in a
Central and Eastern European country. Our findings suggest that de-
pressive symptoms emerge five years before the first cancer hospitali-
sation, for which no biological or biopsychosocial explanations are
confirmed. Our findings highlight the need for early psychological as-
sessment of patients diagnosed with cancer to assess their support
needs. Identifying and treating depression has the potential to improve
quality of life, adherence to treatment, cancer survival, and treatment
costs (Pitman et al., 2018). Evidence-based models of care include the
provision of integrated psychological support service (specialist coun-
sellors and clinical psychologists embedded in cancer services), pro-
viding collaborative screening and treatment (Sharpe et al., 2014).
However, even in well-resourced countries these models of care tend
not to be available outside major urban centres (Pitman et al., 2018).
Integrating mental healthcare into physical healthcare settings is also in
keeping with the WHO's Mental Health Action Plan 2013–2020, espe-
cially in low and middle-income countries (Stein et al., 2019).
5. Conclusions
In conclusion, we found that cancer was an independent predictor of
high depressive symptom burden in a representative sample of adults in
the Czech Republic. This risk was apparent from five years prior to the
first hospitalisation for cancer, and continued for up to 7.5 years after
the first hospitalisation.
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